EW
Edwards Lifesciences
EW · NYSE
$89.90 +0.13% (+$0.12)
1M +0.20%
Market Cap $51.7B
P/E Ratio 51.44x
Div. Yield -
ROE 9.69%
Bulios Fair Price
$47.38
47.3% downside
Current Price
$89.9
Undervalued Fair Value Overvalued
According to Bulios Fair Price, EW is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
14 /100
Expensive EV/EBITDA 32.14x
P/S 7.94x
P/B 4.87x
Growth
41 /100
Stable Rev. growth 4.08%
FCF growth 11.88%
Book val. growth 21.20%
Profitability
98 /100
Strong Net margin 15.43%
Op. margin 28.09%
FCF margin 22.01%
Quality
52 /100
Average ROE 9.69%
ROA 7.25%
Asset turnover 0.47x
Debt
100 /100
Low Current ratio 4.52x
Net debt/EBITDA -1.43x
Debt/Equity 0.07x
Stability
68 /100
Stable Rev. volatility 9.91%
EPS volatility 144.24%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about EW
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Bernard J. Zovighian
Employees
16,000
Headquarters
Irvine
Upcoming events
29 OCT
Earnings
Upcoming earnings report